|1.||Horiuchi, Masatsugu: 12 articles (09/2012 - 03/2005)|
|2.||Sugaya, Takeshi: 12 articles (01/2012 - 03/2002)|
|3.||Sunagawa, Kenji: 11 articles (04/2015 - 09/2006)|
|4.||Ishida, Susumu: 11 articles (01/2013 - 03/2005)|
|5.||Unger, Thomas: 10 articles (05/2015 - 05/2004)|
|6.||Umemura, Satoshi: 10 articles (09/2014 - 03/2003)|
|7.||Fukamizu, Akiyoshi: 9 articles (12/2013 - 02/2004)|
|8.||Tsubota, Kazuo: 9 articles (01/2013 - 03/2005)|
|9.||Nagai, Norihiro: 9 articles (05/2009 - 03/2005)|
|10.||Zou, Yunzeng: 8 articles (08/2015 - 07/2002)|
|1.||Diabetic Nephropathies (Diabetic Nephropathy)
01/01/2014 - "Given a large body of evidence indicating anti-oxidative action of cAMP and up-regulation of cellular cAMP production by SDF-1α, the present results suggest that more powerful DPP-4 inhibition on top of angiotensin II type 1 receptor blockade would offer additional protection against early-stage diabetic nephropathy beyond that attributed to glycemic control, via reduction of renal oxidative stress by SDF-1α-cAMP pathway activation. "
10/01/2002 - "CS-886, a new angiotensin II type 1 receptor antagonist, ameliorates glomerular anionic site loss and prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats."
01/01/2010 - "The present study was undertaken to focus on the effect of local angiotensin II type 1 receptor blockade on the inflammatory reaction during the early stages of diabetic nephropathy. "
11/01/2009 - "In this study, we examined whether the angiotensin II type 1 receptor blocker (ARB) would improve ambulatory short-term BP variability in hypertensive patients with diabetic nephropathy. "
06/01/2008 - "In this study, we examined whether urinary Smad1 in an early phase of diabetes can predict later development of glomerulosclerosis in diabetic nephropathy and how an angiotensin II type 1 receptor blocker (ARB) can modulate structural changes and urinary markers. "
|2.||Hypertension (High Blood Pressure)
01/01/2015 - "This study was performed on primary hypertension patients in a Turkish population to determine the frequency of the A1166C polymorphism in the angiotensin II type 1 receptor (AT1) gene and to examine the role of this polymorphism in hypertension development. "
01/01/2014 - "Effectiveness of using long-acting angiotensin II type 1 receptor blocker in Japanese obese patients with metabolic syndrome on morning hypertension monitoring by using telemedicine system (FUJIYAMA study)."
01/01/2014 - "The purpose of this study was to investigate the association between angiotensin II type 1 receptor (AT1R) gene A(1166)C variants with essential hypertension and some related parameters in a sample of Jordanian hypertensive patients. "
10/01/2013 - "To study the polymorphism of angiotensin-type 1 receptor (AT1R) gene A1166C in familial primary hypertension and its distribution in Han Yellow race of China. "
05/01/2011 - "The main aim of this study was to examine the association of A1166C polymorphism of angiotensin II type 1 receptor and telomere length with essential hypertension in Egyptian people. "
07/27/2004 - "Modulation of the RAAS holds promise for the secondary prevention of stroke, however, ongoing clinical trials will better define the exact role of ACE inhibitor and angiotensin II Type 1 receptor blocker therapy in stroke survivors."
05/01/2015 - "Angiotensin type 1 receptor blockers (ARBs) have induced improved functional recovery and reduced infarct volume in experimental animal models of stroke. "
02/01/2015 - "Angiotensin II type 1 receptor blockade has neuroprotective effects in animal stroke models, but no effects in clinical stroke trials. "
04/01/2013 - "Frequency of angiotensin II type 1 receptor gene polymorphism in Turkish acute stroke patients."
07/01/2012 - "The aim of this retrospective study was to assess the benefits of angiotensin type 1 receptor blockers (ARBs) used before the onset of ischemic stroke. "
09/01/2006 - "Although angiotensin II type 1 receptor blocker (ARB) has been demonstrated to be effective in the treatment of heart failure, information about the potential benefits of ARB on advanced LV failure associated with diabetes is lacking. "
09/01/2002 - "Angiotensin II type 1 receptor antagonist (AIIRA) has been reported to improve exercise capacity and prognosis in patients with congestive heart failure (CHF). "
01/01/2015 - "The aim of this study was to investigate the correlation between the A1166C polymorphism in the angiotensin II type 1 receptor (AT1R) gene and heart failure (HF) risk using meta‑analysis. "
12/01/2013 - "Angiotensin II type 1 receptor (AT1-R) and nuclear factor-kappaB (NF-κB) in the paraventricular nucleus (PVN) play important roles in heart failure (HF); however, the central mechanisms by which AT1-R and NF-κB contribute to sympathoexcitation in HF are yet unclear. "
03/01/2012 - "Central angiotensin type 1 receptor blockade decreases cardiac but not renal sympathetic nerve activity in heart failure."
06/01/2011 - "Angiotensin II type 1 receptor blockade does not enhance apoptotic cell death during ischemia and reperfusion in humans in vivo."
08/01/2007 - "Angiotensin AT1 receptor blockers suppress ischemia/reperfusion-induced gastric injury in rats."
04/01/2005 - "Angiogenic protection from focal ischemia with angiotensin II type 1 receptor blockade in the rat."
10/01/2002 - "Whether AT2R upregulation, associated with angiotensin II type 1 receptor (AT1R) blockade and cardioprotection after ischemia-reperfusion (IR), might not result in increased cardiomyocyte (CM) apoptosis has not been documented. "
08/01/2002 - "Whether AT2R upregulation, associated with angiotensin II type 1 receptor (AT1R) blockade and cardioprotection after ischemia-reperfusion (IR), might not result in increased cardiomyocyte (CM) apoptosis has not been documented. "
|2.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
|8.||Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
|9.||candesartan cilexetil (Amias)
|3.||Transplantation (Transplant Recipients)